Proximal femoral endoprosthesis: Stanmore METS implant (Stryker) with trochanteric reattachment for pathological fracture
Learn the Proximal femoral endoprosthesis: Stanmore METS implant (Stryker) with trochanteric reattachment for pathological fracture surgical technique with step by step instructions on OrthOracle. Our e-learning platform contains high resolution images and a certified CME of the Proximal femoral endoprosthesis: Stanmore METS implant (Stryker) with trochanteric reattachment for pathological fracture surgical procedure.
Endoprosthetic replacements of the proximal femur are one of the most common limb-salvage procedures undertaken to reconstruct massive bone defects secondary to tumour, trauma or infection.
The increasing burden of metastatic bone disease means more cases present to orthopaedic surgeons. Breast cancer is the most common cancer in women and because of advances in systemic therapy, is now considered a chronic disease in many cases. Two thirds of breast cancer patients will develop skeletal metastases which cause skeletal related events (SREs: pathological or impending fracture, hypercalcaemia, spinal cord compression, severe pain) which may require surgery and/or radiotherapy to palliate pain and to preserve mobility and quality of life.
For patients with subtrochanteric bone tumour involvement, fracture and patients with a good prognosis may best be managed with endoprosthetic replacement. Resection of a tumour from the proximal femur requires reconstruction of the large bone and soft-tissue defect and the complications of such surgery from a systematic review include dislocation (5.8%), infection (5.2%), local recurrence (4.7%) and peri-prosthetic fracture (0.6%). These are both reliable and durable implants that offer immediate mobility and return to function; however in the long-term complications and failure mean that ten year implant survival is approximately 75%.
Author :Mr Jonathan Stevenson FRCS (Tr & Orth)
Institution :The Royal Orthopaedic Hospital Birmingham ,UK.
Clinicians should seek clarification on whether any implant demonstrated is licensed for use in their own country.
In the USA contact: fda.gov
In the UK contact: gov.uk
In the EU contact: ema.europa.eu